Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma
Open Access
- 10 March 2020
- Vol. 12 (3), 643
- https://doi.org/10.3390/cancers12030643
Abstract
Medulloblastoma, the most common pediatric malignant brain tumor, continues to have a high rate of morbidity and mortality in childhood. Recent advances in cancer genomics, single-cell sequencing, and sophisticated tumor models have revolutionized the characterization and stratification of medulloblastoma. In this review, we discuss heterogeneity associated with four major subgroups of medulloblastoma (WNT, SHH, Group 3, and Group 4) on the molecular and cellular levels, including histological features, genetic and epigenetic alterations, proteomic landscape, cell-of-origin, tumor microenvironment, and therapeutic approaches. The intratumoral molecular heterogeneity and intertumoral cellular diversity clearly underlie the divergent biology and clinical behavior of these lesions and highlight the future role of precision treatment in this devastating brain tumor in children.Funding Information
- V Foundation for Cancer Research (D2018-025)
This publication has 90 references indexed in Scilit:
- Childhood cerebellar tumours mirror conserved fetal transcriptional programsNature, 2019
- Medulloblastoma: From Myth to MolecularJournal of Clinical Oncology, 2017
- Impact of the physical microenvironment on tumor progression and metastasisCurrent Opinion in Biotechnology, 2016
- Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysisThe Lancet Oncology, 2013
- Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastomaActa Neuropathologica, 2012
- Medulloblastomics: the end of the beginningNature Reviews Cancer, 2012
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Wnt/β-catenin signaling controls development of the blood–brain barrierThe Journal of cell biology, 2008
- Multi-Institution Prospective Trial of Reduced-Dose Craniospinal Irradiation (23.4 Gy) Followed by Conformal Posterior Fossa (36 Gy) and Primary Site Irradiation (55.8 Gy) and Dose-Intensive Chemotherapy for Average-Risk MedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics, 2008
- The fundamental role of epigenetic events in cancerNature Reviews Genetics, 2002